InflaRx N.V.
izicopan
atypical hemolytic uremic syndrome (aHUS)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for izicopan in atypical hemolytic uremic syndrome (aHUS) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“InflaRx estimates it will have sufficient funds to execute currently planned development programs through meaningful milestones, including proof-of-concept data readouts in aHUS, IgAN and C3G, the Phase 2 data readout in AAV, as well as ong”